Regulatory Guide to Labelling, Packaging and Traceability in ATMPs: Ensuring Safety and Compliance

Introduction to Labelling, Packaging, and Traceability in ATMPs

Advanced Therapy Medicinal Products (ATMPs) — including gene therapies, somatic-cell therapies, and tissue-engineered products — present unique regulatory challenges due to their complexity, patient specificity, and logistical requirements. Unlike conventional medicines, ATMPs may be prepared on a per-patient basis, requiring robust systems for labelling, packaging, and traceability. Global regulators such as the FDA, the EMA, and the CDSCO mandate strict requirements to ensure product integrity, patient safety, and regulatory compliance.

By 2025, regulatory agencies are intensifying focus on chain-of-identity (COI), chain-of-custody (COC), serialization, and digital traceability systems, making these elements central to ATMP approval and lifecycle management.

Key Concepts in ATMP Labelling, Packaging, and Traceability

Several regulatory concepts underpin compliance in this area:

• Labelling: Includes product identity, patient-specific identifiers, storage conditions, expiry, and safety warnings.
• Packaging: Must maintain sterility, cold chain integrity, and tamper-evidence.
• Traceability: Systems ensuring product tracking across manufacturing, distribution, and administration.
• Chain-of-Identity (COI): Ensures patient-specific ATMPs are linked to the correct recipient.
• Chain-of-Custody (COC): Documents each handoff to maintain integrity and accountability.

These elements form the foundation of ATMP regulatory compliance and patient safety frameworks.

Global Regulatory Frameworks

Different jurisdictions define labelling, packaging, and traceability requirements for ATMPs:

• FDA (US): Requires compliance under 21 CFR Parts 210, 211, and 1271. Autologous therapies require patient-specific labels with COI and COC documentation. REMS programs often include packaging safeguards.
• EMA (EU): Annex 13 of EU GMP and Regulation (EC) No 1394/2007 mandate serialization, tamper-evidence, and robust COI/COC systems for ATMPs.
• CDSCO (India): Draft ATMP guidance aligns with WHO and EMA standards, requiring secure labelling and traceability frameworks integrated with PvPI systems.
• Other Jurisdictions: Japan PMDA and Brazil ANVISA emphasize conditional approvals tied to traceability obligations.

These frameworks are evolving toward harmonization under ICH and WHO initiatives.

Processes and Workflow for Compliance

A step-by-step workflow ensures compliant labelling, packaging, and traceability:

1. Product Identification: Assign patient-specific identifiers or serialization codes.
2. Labelling Preparation: Include regulatory-approved content (product name, patient ID, storage, expiry, warnings).
3. Packaging Operations: Use tamper-evident, sterile, and cold-chain compliant packaging.
4. Traceability Systems: Implement COI/COC tracking using barcoding, RFID, or blockchain tools.
5. Documentation: Maintain batch records, shipment logs, and custody transfer documents.
6. Distribution and Delivery: Ensure qualified logistics partners manage cold chain and COI/COC transfers.
7. Regulatory Submissions: Submit labelling and packaging details in CTD Module 3 and inspection readiness packages.

This workflow integrates GMP, regulatory, and logistics requirements into ATMP lifecycle management.

Case Study 1: FDA CAR-T Therapy Labelling

Case: FDA approved a CAR-T therapy in 2022 with strict labelling requirements.

• Challenge: Patient-specific product needed accurate COI documentation.
• Action: Implemented barcode-based COI/COC tracking integrated with electronic health records.
• Outcome: FDA approved the BLA with COI/COC systems as part of REMS.
• Lesson Learned: Digital tracking reduces risk of patient–product mismatch.

Case Study 2: EMA Tissue-Engineered Product Packaging

Case: EMA assessed a tissue-engineered product requiring cold chain packaging across multiple EU sites.

• Challenge: Cold chain breaches during cross-border transport raised inspection concerns.
• Action: Introduced tamper-evident insulated containers with real-time temperature monitoring.
• Outcome: EMA approved centralized MAA with packaging safeguards.
• Lesson Learned: Packaging systems must combine sterility assurance with logistics resilience.

Tools, Templates, and Systems for Compliance

RA professionals use specialized tools for ATMP labelling, packaging, and traceability:

• Label Templates: Standardized regulatory-compliant formats for FDA, EMA, and CDSCO.
• Serialization Systems: Digital platforms for assigning and verifying product identifiers.
• Blockchain Traceability Tools: Advanced solutions for COI/COC and regulatory audits.
• Cold Chain Monitoring Systems: IoT-enabled sensors and alarms for transport compliance.
• Inspection Checklists: Templates covering labelling, packaging, and traceability compliance.

These tools improve inspection readiness and reduce regulatory risks.

Common Challenges and Best Practices

ATMP sponsors face recurring challenges in labelling, packaging, and traceability:

• Patient-Specific Complexity: Autologous products require individualized labelling and traceability.
• Cold Chain Integrity: ATMPs often have extremely short shelf lives requiring flawless logistics.
• Global Divergence: Different jurisdictions mandate varying levels of serialization and traceability.
• Resource Burden: Implementation of blockchain or RFID-based systems can be costly.

Best practices include harmonizing global labelling strategies, investing in digital COI/COC platforms, engaging regulators early, and adopting real-time logistics monitoring.

Latest Updates and Strategic Insights

By 2025, labelling, packaging, and traceability in ATMPs are influenced by new trends:

• Digital Transformation: Increasing adoption of AI and blockchain for serialization and traceability.
• Harmonization: ICH discussions on ATMP-specific labelling and packaging standards.
• Cold Chain Innovation: Development of smart containers with predictive analytics for temperature stability.
• Inspection Focus: Regulators intensifying inspections on COI/COC systems during audits.
• Patient-Centric Labelling: Clearer labelling for healthcare providers and patients to reduce risks.

Strategically, RA professionals must integrate digital traceability and harmonized labelling approaches to align with 2025 expectations.

Conclusion

Labelling, packaging, and traceability are central to ATMP safety and compliance, ensuring that complex and patient-specific products reach the right recipient under secure conditions. By mastering FDA, EMA, and CDSCO requirements, RA professionals can mitigate risks, prepare for inspections, and sustain regulatory confidence. In 2025 and beyond, digital tools, harmonization, and innovation will redefine compliance strategies in this critical area of ATMP lifecycle management.